ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

2.46
-0.13
( -5.02% )
Updated: 11:21:44

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
2.46
Bid
2.45
Ask
2.46
Volume
98,155
2.46 Day's Range 2.56
1.32 52 Week Range 3.97
Market Cap
Previous Close
2.59
Open
2.53
Last Trade
2
@
2.4569
Last Trade Time
11:24:59
Financial Volume
$ 247,453
VWAP
2.521
Average Volume (3m)
798,219
Shares Outstanding
254,096,311
Dividend Yield
-
PE Ratio
-2.73
Earnings Per Share (EPS)
-0.92
Revenue
2.92M
Net Profit
-234.63M

About Lyell Immunopharma Inc

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Lyell Immunopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LYEL. The last closing price for Lyell Immunopharma was $2.59. Over the last year, Lyell Immunopharma shares have traded in a share price range of $ 1.32 to $ 3.97.

Lyell Immunopharma currently has 254,096,311 shares outstanding. The market capitalization of Lyell Immunopharma is $640.32 million. Lyell Immunopharma has a price to earnings ratio (PE ratio) of -2.73.

LYEL Latest News

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0251.026694045172.4352.6752.2510821552.55360633CS
4-0.32-11.51079136692.782.8752.257601172.62948413CS
120.4421.78217821782.023.1451.97982192.47820156CS
260.3617.14285714292.13.25561.6910185912.24244706CS
52-0.86-25.90361445783.323.971.329691842.26113256CS
156-16.29-86.8818.7519.841.329308254.73068055CS
260-16.29-86.8818.7519.841.329308254.73068055CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.22
(283.82%)
40.69M
SVMHSRIVARU Holding Ltd
$ 0.318
(108.52%)
204.79M
TOIIWOncology Institute Inc
$ 0.032
(75.82%)
58.62k
CNSPCNS Pharmaceuticals Inc
$ 5.915
(63.40%)
4.62M
ARECAmerican Resources Corporation
$ 1.07
(44.59%)
2.99M
GANXGain Therapeutics Inc
$ 1.2798
(-32.29%)
1.9M
NXLNexalin Technologies Inc
$ 0.9389
(-31.98%)
2.7M
INABIN8bio Inc
$ 1.1704
(-30.33%)
2.46M
KYTXKyverna Therapeutics Inc
$ 10.40
(-27.98%)
2M
QXOQXO Inc
$ 148.9154
(-27.50%)
98.14k
SVMHSRIVARU Holding Ltd
$ 0.318
(108.52%)
204.79M
NVDANVIDIA Corporation
$ 131.34
(1.33%)
130.78M
LGVNLongeveron Inc
$ 3.7199
(38.29%)
71.18M
KITTNauticus Robotics Inc
$ 0.22
(37.07%)
58.16M
SQQQProShares UltraPro Short QQQ
$ 8.5097
(-0.35%)
47.98M

LYEL Discussion

View Posts
glenn1919 glenn1919 2 months ago
LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
LYEL active in the Gaucho session

👍️0
jondoeuk jondoeuk 2 months ago
Tempting but I will remain on the sidelines.
👍️0
Monksdream Monksdream 2 months ago
LYEL under $3
👍️0
glenn1919 glenn1919 3 months ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 7 months ago
They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
👍️0
jondoeuk jondoeuk 9 months ago
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
Monksdream Monksdream 9 months ago
LYEL new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
👍️0
jondoeuk jondoeuk 1 year ago
Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
👍️0
glenn1919 glenn1919 1 year ago
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 2 years ago
The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
👍️0
jondoeuk jondoeuk 2 years ago
SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
👍️0
NY1972 NY1972 2 years ago
recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
👍️0
jondoeuk jondoeuk 2 years ago
The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
👍️0
NY1972 NY1972 2 years ago
Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

👍️0
jondoeuk jondoeuk 2 years ago
For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
👍️0
NY1972 NY1972 2 years ago
Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
👍️0
jondoeuk jondoeuk 2 years ago
That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
👍️0
NY1972 NY1972 2 years ago
Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
👍️0
jondoeuk jondoeuk 2 years ago
ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
👍️0
jondoeuk jondoeuk 2 years ago
Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
👍️0
jondoeuk jondoeuk 2 years ago
1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
👍️0
jondoeuk jondoeuk 2 years ago
GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.
👍️0
jondoeuk jondoeuk 2 years ago
AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6
👍️0
jondoeuk jondoeuk 2 years ago
The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.
👍️0
jondoeuk jondoeuk 3 years ago
A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278
👍️0
jondoeuk jondoeuk 3 years ago
Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917
👍️0
jondoeuk jondoeuk 3 years ago
New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
👍️0

Your Recent History

Delayed Upgrade Clock